Article

Lifelong follow-up essential in testis Ca patients

Orlando, FL-A study by researchers from Memorial Sloan-Kettering Cancer Center in New York has given added strength to the recommendation that patients who develop unilateral testicular germ cell tumors should be followed carefully over their lifetimes. The interval between development of a first and second tumor can be 20 or more years, according to their retrospective, 50-year review.

Related Videos
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Marah C. Hehemann, MD, answers a question during a video interview
Crop shot of senior man sitting on sofa with doctor during home visit taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
Olivia Paulsen answers a question during a video interview
Evan Panken, MD, answers a question during a video interview
Oliver Sartor, MD, is featured in this series.
Related Content
Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB
October 24th 2024

Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB

Hannah Clarke
At 1 month, the mean decrease in the OAB-Q symptom severity subscale score was -31.2 in the 1-injection cohort vs -39.5 in the 10-injection cohort.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
FDA grants 510(k) clearance to Ambu’s HD cystoscopy solution
October 23rd 2024

FDA grants 510(k) clearance to Ambu’s HD cystoscopy solution

Hannah Clarke
The cystoscopy solution was granted a CE mark for regulatory clearance in Europe in October 2023.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Category I CPT code granted to irreversible electroporation for prostate lesions
October 22nd 2024

Category I CPT code granted to irreversible electroporation for prostate lesions

Hannah Clarke
The codes will go into effect on January 1, 2026.
TikTok content on low testosterone lacks information on future risks, study finds
October 22nd 2024

TikTok content on low testosterone lacks information on future risks, study finds

Hannah Clarke
None of the videos mentioned the long-term impact of exogenous testosterone on spermatogenesis.
© 2024 MJH Life Sciences

All rights reserved.